Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Liabilities and Shareholders Equity (2016 - 2025)

Editas Medicine (EDIT) has disclosed Liabilities and Shareholders Equity for 11 consecutive years, with $201.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 38.41% to $201.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.0 billion, a 38.4% decrease, with the full-year FY2024 number at $341.6 million, down 31.57% from a year prior.
  • Liabilities and Shareholders Equity was $201.8 million for Q3 2025 at Editas Medicine, down from $210.6 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $780.3 million in Q1 2021 to a low of $201.8 million in Q3 2025.
  • A 5-year average of $492.6 million and a median of $504.6 million in 2023 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: surged 67.18% in 2021, then tumbled 45.28% in 2025.
  • Editas Medicine's Liabilities and Shareholders Equity stood at $677.5 million in 2021, then dropped by 24.08% to $514.3 million in 2022, then decreased by 2.95% to $499.2 million in 2023, then plummeted by 31.57% to $341.6 million in 2024, then tumbled by 40.94% to $201.8 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Liabilities and Shareholders Equity are $201.8 million (Q3 2025), $210.6 million (Q2 2025), and $263.7 million (Q1 2025).